

## Scientific Poster Presentations, III

### Wednesday, October 16

Convention Center:

Fran Hill NE Exhibit Hall

8:00 a.m.–10:00 a.m.

### ENCORE PRESENTATIONS

Abstracts marked with an “E” are Encore Presentations. Encore Presentations undergo the same peer-review process as all other presentations, but they may have been presented elsewhere or published in abstract form before the 2013 ACCP Annual Meeting. For presentations, the abstract title, authors, and original citation (if provided) are published.

### AWARDS COMPETITION

Abstracts marked with an “F” listed on pages 156–159 are finalists for the Best Student Poster, Best Resident and Fellow Poster, and Best Paper awards. These papers were selected by a special panel of reviewers.

### ORIGINAL RESEARCH

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoconomics, and pharmacoepidemiology.

### ADR/Drug Interactions

1. Adverse Drug Reaction–Related Hospitalizations in a Chinese Hospital: A Prospective Study.

*Man Zhu, Master*;<sup>1</sup> *Zhihui Tang, Master*;<sup>2</sup> *Daihong Guo, Master*;<sup>2</sup> *Dongxiao Wang, Master*;<sup>2</sup> *Weilan Wang, Master*;<sup>2</sup> *Fei Pei, Master*;<sup>2</sup> (1)Department of Pharmaceutical Care, Chinese PLA General Hospital, Beijing, China; (2)Chinese PLA General Hospital, Beijing, China

2. Association Between Thromboembolic Complications and Recombinant Factor VIIa When Used in Non-hemophiliacs.

*Shawn Johnson, Pharm.D., MPH, BCPS, BCNSP*;<sup>1</sup> *Danielle Blais, Pharm.D., BCPS*;<sup>2</sup> *Erin Reichert, Pharm.D., BCPS*;<sup>1</sup> *Pamela Burcham, Pharm.D., BCPS*;<sup>1</sup> *Anthony Gerlach, Pharm.D., FCCM, BCPS*;<sup>3</sup> (1)The Ohio State University Wexner Medical Center; (2)The Ohio State University Wexner Medical Center; (3)Pharmacy, The Ohio State University Wexner Medical Center

### Adult Medicine

3. Asymptomatic Bacteriuria in Adult Acute Care Patients: A Descriptive Analysis.

*Ryan Dull, Pharm.D.*;<sup>1</sup> *Stacey Friedman, Pharm.D.*;<sup>2</sup> *Meghan Doyle, Pharm.D. Candidate*;<sup>2</sup> *Brianne Davis, Pharm.D. Candidate*;<sup>2</sup> (1)Department of Pharmacy Practice, Creighton University School of Pharmacy and Health Professions, Omaha, NE; (2)Creighton University School of Pharmacy and Health Professions, Omaha, NE

### Ambulatory Care

5. Description of Fracture Risk in Postmenopausal Women on Long-term Bisphosphonate Therapy in Primary Care.

*Matthew Kostoff, Pharm.D., BCPS*, *Laura Borgelt, Pharm.D., FCCP, BCPS*, *Joseph Saseen, Pharm.D.*; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

7. Therapeutic Outcomes of a Pharmacist-Directed Attention Deficit-Hyperactivity Disorder Program in a Medical Home.

*Jennifer Reinhold, Pharm.D.*,<sup>1</sup> Vincent Willey, Pharm.D.,<sup>1</sup> Kathleen Willey, M.D.,<sup>2</sup> Bonnie Kelly, M.D.,<sup>2</sup> Eun Kim, M.D.,<sup>2</sup> Miriam Mullin, M.D.<sup>2</sup>; (1)Philadelphia College of Pharmacy, Philadelphia, PA; (2)Quality Family Physicians, Hockessin, DE

8. Survey of Pharmacist Management of Subtherapeutic INRs and Parenteral Anticoagulant Bridging Practices During Vitamin K Antagonist Therapy.

*Whitney D. Maxwell, Pharm.D., BCPS*,<sup>1</sup> Sarah P. Shrader, Pharm.D., BCPS,<sup>2</sup> Sarah F. White, Pharm.D., BCPS,<sup>3</sup> Katherine G. Moore, Pharm.D., BCPS, BCACP<sup>4</sup>; (1)South Carolina College of Pharmacy-USC Campus, Columbia, SC; (2)University of Kansas School of Pharmacy, Lawrence, KS; (3)Sullivan University College of Pharmacy, Lexington, KY; (4)Presbyterian College School of Pharmacy, Clinton, SC

9. Association Between Prescription Drug Benefit and Hospital Readmission Rates.

*Laura Challen, Pharm.D., BCPS, MBA*,<sup>1</sup> Christine Kelso, Pharm.D., BCPS, AE-C,<sup>2</sup> Bhumi Gandhi, Pharm.D. Candidate<sup>3</sup>; (1)Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, MO; (2) Barnes-Jewish Hospital; (3)St. Louis College of Pharmacy

10. Retrospective Case-Control Study Comparing Twice-Daily Insulin Glargine and Insulin Detemir in Veteran Patients with Type 2 Diabetes.

*Timothy Harmon, Pharm.D.*,<sup>1</sup> Thomas J. Worrall, Pharm.D., BS(Pharm)<sup>2</sup>; (1)Ralph H. Johnson VAMC, Charleston, SC; (2)Ralph H. Johnson VA Medical Center, Charleston, SC

11. Evaluation of Safety and Effectiveness of 12-Week Monitoring of Patients Stable on Warfarin at UC Davis Anticoagulation Clinic.

*Jennifer Nguyen, Pharm.D.*,<sup>1</sup> Teresa Kwong, Pharm.D.,<sup>2</sup> Julie Dang, Pharm.D.<sup>2</sup>; (1)Department of Pharmacy, UC Davis Medical Center, Sacramento; (2)UC Davis Medical Center, Sacramento, CA

12F. Impact of a Medicaid Prescription Limitation Policy on Health Care Utilization.

*Megan Fleischman, Pharm.D.*,<sup>1</sup> Deanne L. Hall, Pharm.D.,<sup>2</sup> Gary Fischer, M.D.,<sup>3</sup> John Donehoo, BS(Pharm),<sup>4</sup> Arletta Yahnke, BS(Pharm),<sup>4</sup> Ty Ridenour, Ph.D., MPE<sup>5</sup>; (1)Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA; (3)University of Pittsburgh School of Medicine/University of Pittsburgh Medical Center; (4) University of Pittsburgh Medical Center; (5)University of Pittsburgh School of Pharmacy

13. Assessing Time to Failure of Maintain Blood Pressure Goals in Patients with Diabetes Discharged from a Veterans Affairs Medical Center (VAMC) Pharmacist-Managed Primary Care Clinic.

*Golden Peters, Pharm.D., BCPS*, P. Benjamin Erwin, Pharm.D., BCACP, Matthew Pitlick, Pharm.D., BCPS; St. Louis College of Pharmacy, St. Louis, MO

14. Implementation of a Clinical Pharmacist-Directed Hospital Discharge Service to Improve Transitions in Care.

*Anita Sharma, Pharm.D.*, Chrystian R. Pereira, Pharm.D.; University of Minnesota College of Pharmacy, Minneapolis, MN

15E. Impact of Ramadan Fasting on HbA1c in Relation to Medication Use.

Melanie Siaw, BSc(Pharm)(Hons),<sup>1</sup> Nur Hidayah Bte Shamsuri, BSc(Pharm)(Hons),<sup>1</sup> Daniel Chew, MBBS, MRCP (UK), FAMS,<sup>2</sup> Rinkoo Dalan, MBBS, MRCP (UK), FAMS (Endocrinology), FRCP (Edin),<sup>2</sup> S.A. Abdul Shakoor, MBBS, M.D. (General Medicine, India), MRCP (UK), M.D. (Newcastle University, UK),<sup>2</sup> Noorani Othman, CDE,<sup>2</sup> Theresa Choo, MSc(Clin Pharm),<sup>3</sup> Siti Nurhannah Abdul Karim, BSc(Pharm)(Hons),<sup>3</sup> Olive Lai, Pharm.D.,<sup>1</sup> Joyce Lee, Pharm.D., BCPS,

BCACP<sup>1</sup>; (1)Department of Pharmacy, Faculty of Science at National University of Singapore, Singapore; (2)Department of Endocrinology, Tan Tock Seng Hospital, Singapore; (3)Department of Pharmacy, Tan Tock Seng Hospital, Singapore

16. Evaluation of Pharmacist Intervention in Hepatitis C Care Management.

*Katherine Gazlay, Pharm.D.*,<sup>1</sup> Jason Bailly, Pharm.D.,<sup>1</sup> Linda Awdishu, Pharm.D.,<sup>2</sup> Charles James, Pharm.D.,<sup>1</sup> Shirley Tsunoda, Pharm.D.;<sup>2</sup> (1)University of California, San Diego Health System, San Diego, CA; (2)University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA

17. Hospitalizations and Patient Outcomes After Referral to a Pharmacist-Physician Diabetes Co-management Service.

*Anita Airee, Pharm.D.*, BCPS,<sup>1</sup> Andrew W. Dake, M.D.,<sup>2</sup> Juli D. Williams, M.D.,<sup>2</sup> Patrick B. Barlow, B.A.,<sup>2</sup> R. Eric Heidel, Ph.D.,<sup>2</sup> Matthew A. Rubertus, Pharm.D. Candidate,<sup>3</sup> Abel M. Yehdego, Pharm.D. Candidate,<sup>3</sup> Michelle Z. Farland, Pharm.D., BCPS, CDE<sup>4</sup>; (1)Department of Clinical Pharmacy, The University of Tennessee College of Pharmacy, Knoxville Campus, Knoxville, TN; (2)Graduate School of Medicine, The University of Tennessee Medical Center, Knoxville, Knoxville, TN; (3)The University of Tennessee College of Pharmacy, Knoxville Campus, Knoxville, TN; (4)University of Tennessee Health Science Center College of Pharmacy, Knoxville, TN

### Community Pharmacy Practice

35. Implications of Medicare Part D on Community Pharmacy: A Nationwide Study.

*Shamima Khan, MBA, Ph.D.*,<sup>1</sup> Joshua Spooner, Pharm.D., M.S.,<sup>1</sup> Christopher Hakala, Ph.D.,<sup>2</sup> Evan Robinson, RPh, Ph.D.;<sup>1</sup> (1)College of Pharmacy, Western New England University, Springfield, MA; (2)College of Arts & Sciences, Western New England University, Springfield, MA

### Critical Care

36. Association of Venous Thromboembolism (VTE) with Missed Doses of Prophylactic Antithrombotic Medications in High-Risk Patients.

*Stacy A. Voils, Pharm.D., M.S.*,<sup>1</sup> Alexa Carlson, Pharm.D.;<sup>2</sup> (1)Virginia Commonwealth University Health System, Richmond, VA; (2)Northeastern University School of Pharmacy, Boston, MA

37. Influence of Dexmedetomidine Therapy on the Management of Severe Alcohol Withdrawal Syndrome in Critically Ill Patients.

*Erin N. Frazee, Pharm.D.*, Heather A. Personett, Pharm.D., Jonathan Leung, Pharm.D., Sarah Nelson, Pharm.D., Ross Dierkhising, M.S., Philippe Bauer, M.D., Ph.D.; Mayo Clinic, Rochester, MN

38. Midodrine for Weaning of Vasopressor Infusions.

*Elizabeth Michalets, Pharm.D.*, FCCP, BCPS,<sup>1</sup> Laura Poveromo, Pharm.D.,<sup>2</sup> Susan Sutherland, Ph.D.;<sup>3</sup> (1)Mission Health System and UNC Eshelman School of Pharmacy, Asheville, NC; (2) Mission Health System Department of Pharmacy, Asheville, NC; (3)Mission Health System Research Institute, Mission Health System, Asheville, NC

39. Outcomes Associated with Prothrombin Complex Concentrate for International Normalized Ratio Reversal in Patients on Oral Anticoagulants with Acute Bleeding.

*Elizabeth Michalets, Pharm.D.*, FCCP, BCPS,<sup>1</sup> Ryan Tilton, Pharm.D.,<sup>2</sup> Bethany S. Delk, Pharm.D., BCPS;<sup>2</sup> (1)Mission Health System and UNC Eshelman School of Pharmacy, Asheville, NC; (2)Department of Pharmacy, Mission Health System, Asheville, NC

40E. High-Dose Dexmedetomidine Is Not Associated with Increased Risk of Hypotension. Anthony Gerlach, Pharm.D., FCCM, BCPS,<sup>1</sup> Danielle Blais, Pharm.D., BCPS,<sup>2</sup> G. Morgan Jones, Pharm.D., BCPS,<sup>3</sup> Pamela Burcham, Pharm.D., BCPS,<sup>4</sup> Stansilaw Stawicki, M.D.,<sup>5</sup> Charles Cook, M.D., FACS, FCCM,<sup>5</sup> Claire Murphy, Pharm.D., BCPS<sup>4</sup>; (1)Pharmacy, The Ohio State University Wexner Medical Center; (2)The Ohio State University Wexner Medical Center; (3)Pharmacy, Methodist University Hospital, Memphis, TN; (4)The Ohio State University Wexner Medical Center; (5)Surgery, The Ohio State University Wexner Medical Center

### Education/Training

57. Implementation and Measurement of an Activity to Foster a Sense of Community Among Pharmacy Students at Distance Locations. Kelly Cochran, Pharm.D., BCPS,<sup>1</sup> Erica Ottis, Pharm.D., BCPS,<sup>1</sup> Daniel Aistrope, Pharm.D.,<sup>1</sup> Linda Garavalia, Ph.D.,<sup>2</sup> Maqual Graham, Pharm.D.<sup>2</sup>; (1)Division of Pharmacy Practice & Administration, University of Missouri-Kansas City School of Pharmacy at MU, Columbia, MO; (2)Division of Pharmacy Practice & Administration, University of Missouri-Kansas City School of Pharmacy, Kansas City, MO

### Gastroenterology

77. Proton Pump Inhibitors and *Clostridium difficile*-Associated Diarrhea: When Does Risk Increase? Jeffrey Barletta, Pharm.D., Shareen El-Ibiary, Pharm.D., Lindsay Davis, Pharm.D., Bao Nguyen, Pharm.D., Carrington (Kip) Raney, Pharm.D.; Department of Pharmacy Practice, Midwestern University, College of Pharmacy – Glendale, Glendale, AZ

78. Impact of *Helicobacter pylori* Treatment on Nonsteroidal Anti-inflammatory Drugs (NSAIDs)-Induced Ulcer Formation in Adult Patients: A Meta-analysis. Tantri Budiman, Pharm.D.,<sup>1</sup> Bingle John Fontanosa, MT<sup>2</sup>; (1)Department of Pharmacy, Sage Memorial Hospital, Ganado, AZ; (2)Sage Memorial Hospital, Ganado, AZ

79. Evaluating the Incidence and Treatment of Telaprevir-Induced Rash. Michael A. Smith, Pharm.D., BCPS,<sup>1</sup> Heather J. Johnson, Pharm.D., BCPS,<sup>1</sup> Ashley M. Ulrich, B.S.,<sup>2</sup> Kapil B. Chopra, M.D.,<sup>2</sup> Michael A. Dunn, M.D.,<sup>2</sup> Rima A. Mohammad, Pharm.D., BCPS<sup>1</sup>; (1)University of Pittsburgh School of Pharmacy, Pittsburgh, PA; (2)University of Pittsburgh School of Medicine, Pittsburgh, PA

81. Project ECHO (Extension for Community Healthcare Outcomes) Expands Access to Hepatitis C Treatment for Underserved Populations. Paulina Deming, Pharm.D.,<sup>1</sup> Karla Thornton, M.D., MPH,<sup>2</sup> Summers Kalishman, Ph.D.,<sup>2</sup> Glenn Murata, M.D.,<sup>2</sup> Sanjeev Arora, M.D.<sup>2</sup>; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)Project ECHO, University of New Mexico, Albuquerque, NM

### Health Services Research

86. Type 2 Diabetes Mellitus Among Medicare Beneficiaries in 2011: Overall and Subgroup Prevalence, Comorbidities and Hypoglycemia. Robert Bailey, M.D.,<sup>1</sup> Janice Lopez, Pharm.D., MPH,<sup>1</sup> Huai-Che Shih, NA,<sup>2</sup> Sharanya Murty, NA,<sup>2</sup> Rachel Feldman, MPA<sup>2</sup>; (1)Janssen Scientific Affairs, LLC; (2)The Moran Company

87. A Multidisciplinary Intervention for Reducing Readmissions Among Older Adults in a Patient-Centered Medical Home. Paul Stranges, Pharm.D., BCPS,<sup>1</sup> Tami Remington, Pharm.D., BCPS<sup>2</sup>; (1)Department of Pharmacy, University of Michigan, Ann Arbor, MI; (2)University of Michigan, Ann Arbor, MI

88. What Are the Appropriate Clinical Pharmacy Key Performance Indicators for Hospital Pharmacists?

Olavo Fernandes, Pharm.D.,<sup>1</sup> Sean Gorman, Pharm.D.,<sup>2</sup> Richard Slavik, Pharm.D.,<sup>2</sup> William Semchuk, Pharm.D.,<sup>3</sup> Douglas Doucette, Pharm.D.,<sup>4</sup> Heather Bannerman, Pharm.D.,<sup>5</sup> Jennifer Lo, Pharm.D.,<sup>5</sup> Simone Shukla, Pharm.D.,<sup>5</sup> Winnie Chan, Pharm.D.,<sup>5</sup> Natalie Benninger, Pharm.D.,<sup>5</sup> Neil MacKinnon, Ph.D.,<sup>6</sup> Chaim Bell, Ph.D.,<sup>7</sup> Jeremy Slobodan, BSc(Pharm),<sup>8</sup> Catherine Lyder, MHSA,<sup>9</sup> Peter Zed, Pharm.D.,<sup>10</sup> Kent Toombs, BSc(Pharm)<sup>11</sup>; (1)University Health Network, Toronto, ON, Canada; (2)Interior Health Authority, Kelowna, BC, Canada; (3)Regina Qu'Appelle Health Region, Regina, SK, Canada; (4)Horizon Health Network, Moncton, NB, Canada; (5)University of Toronto, Toronto, ON, Canada; (6)University of Arizona, Tucson, AZ; (7)Mount Sinai Hospital, Toronto, ON, Canada; (8)Alberta Health Services, Red Deer, AB, Canada; (9)Canadian Society of Hospital Pharmacists, Ottawa, ON, Canada; (10)University of British Columbia, Vancouver, BC, Canada; (11)Capital District Health Authority, Halifax, NS, Canada

89. Care Transitions Service: An Inpatient Pharmacy-Driven Medication Reconciliation Service.

John Togami, Pharm.D.,<sup>1</sup> Jessica Conklin, Pharm.D.,<sup>2</sup> Gretchen Ray, Pharm.D.,<sup>2</sup> Allison Burnett, Pharm.D.,<sup>1</sup> Melanie Dodd, Pharm.D.<sup>2</sup>; (1)Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, NM; (2)College of Pharmacy, University of New Mexico, Albuquerque, NM

### Herbal/Complementary Medicine

93. Evaluating the Effects of Krill Oil, Supplemental Fish Oil, and Prescription Fish Oil on Lipoproteins and Gastrointestinal Symptoms – A Randomized Controlled Trial.

Janelle F. Ruisinger, Pharm.D.,<sup>1</sup> James M. Backes, Pharm.D.,<sup>2</sup> Kristina Harris, Ph.D.,<sup>3</sup> Cheryl Gibson, Ph.D.,<sup>4</sup> William Harris, Ph.D.,<sup>5</sup> Patrick M. Moriarty, M.D.<sup>6</sup>; (1)University of Kansas School of Pharmacy Department of Pharmacy Practice, University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS; (2)Mail Stop 4047, University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS; (3)OmegaQuant, LLC, Sioux Falls, SD; (4)Kansas University Medical Center, Kansas City, KS; (5)Health Diagnostic Laboratory, Inc., Richmond, VA; (6)University of Kansas Atherosclerosis and LDL-Apheresis Center, Kansas City, KS

94. Hemodynamic and Electrocardiographic Effects of Acai Berry in Healthy Volunteers: A Randomized Controlled Trial.

Ashley Gale, B.S.,<sup>1</sup> Rajbir Kaur, Pharm.D.,<sup>2</sup> William L. Baker Jr, Pharm.D.<sup>1</sup>; (1)University of Connecticut School of Pharmacy, Storrs, CT; (2)Hartford Hospital, Hartford, CT

### HIV/AIDS

95E. 96-Week Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF – Subgroup Analyses by Baseline HIV-1 RNA and CD4 Cells.

Andrew Zolopa, M.D.,<sup>1</sup> Jurgen Rockstroh, M.D.,<sup>2</sup> Chloe Orkin, M.D.,<sup>3</sup> Hans-Jurgen Stellbrink, M.D.,<sup>4</sup> Sharon Walmsley, M.D.,<sup>5</sup> David Cooper, M.D.,<sup>6</sup> Lijie Zhong, M.D., Ph.D.,<sup>7</sup> Marshall Fordyce, M.D.,<sup>7</sup> Martin Rhee, M.D.,<sup>7</sup> Mark Bernstein, RPh, MBA,<sup>7</sup> Jason T. Hindman, Pharm.D., MBA,<sup>7</sup> Javier Szwarcberg, M.D., MPH<sup>7</sup>; (1)Stanford University, Palo Alto, CA; (2)University of Bonn, Germany; (3)Barts and the London NHS Trust, London, United Kingdom; (4)ICH Study Center, Hamburg, Germany; (5)Toronto General Hospital, Toronto, Canada; (6)St. Vincent's Hospital, Sydney, Australia; (7)Gilead Sciences, Foster City, CA

96. Evaluation of the Occurrence of Antiretroviral and Opportunistic Prophylaxis Medication Errors Within the Inpatient Setting.

Thomas Chiampas, Pharm.D., Melissa E. Badowski, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, IL

97. Predictors of Glycemic Control Among HIV-Positive Veterans with Diabetes.

Marie Davies, Pharm.D., MSCR,<sup>1</sup> Melissa Johnson, Pharm.D., MHS, AAHIVP,<sup>2</sup> *Jamie Brown, Pharm.D., BCPS,*<sup>3</sup> Mary Townsend, Pharm.D., AAHIVP<sup>4</sup>; (1)Durham VA Medical Center, Durham, NC; (2)Duke University Medical Center, Durham, NC; (3)Pharmacy Service, Durham VA Medical Center, Durham, NC; (4)Campbell University College of Pharmacy & Health Sciences, Buies Creek, NC

98E. Simplification to Abacavir/Lamivudine (ABC/3TC) + Atazanavir (ATV) from Tenofovir/ Emtricitabine (TDF/FTC) + ATV/Ritonavir (r) Maintains Viral Suppression and Improves Bone Biomarkers: 48-Week ASSURE Study Results.

David A. Wohl, M.D.,<sup>1</sup> Laveeza Bhatti, M.D., Ph.D.,<sup>2</sup> Catherine B. Small, M.D.,<sup>3</sup> Howard E. Edelstein, M.D.,<sup>4</sup> Henry Zhao, Ph.D.,<sup>5</sup> David A. Margolis, M.D.,<sup>5</sup> Lisa L. Ross, M.S.,<sup>5</sup> *Mark S. Shaefer, Pharm.D.*<sup>6</sup>; (1)University of NC at Chapel Hill School of Medicine, Division of Infectious Disease, Chapel Hill, NC; (2)AIDS Healthcare Foundation, Beverly Hills, CA; (3)New York Medical College, Valhalla, NY; (4)Alameda County Medical Center, Oakland, CA; (5)GlaxoSmithKline, Research Triangle Park, NC; (6)Head, Medical Affairs North America, ViiV Healthcare, Durham, NC

99. Adherence to Antiretroviral Therapy and the Association with Treatment Experience Among Commercially Insured and Medicaid HIV Patients in the United States.

Jennifer Korsnes, M.S.,<sup>1</sup> *Bridgett Goodwin, M.S.,*<sup>2</sup> Sean Candrilli, Ph.D.<sup>1</sup>; (1)RTI Health Solutions, Research Triangle Park, NC; (2)GlaxoSmithKline, Research Triangle Park, NC

100. Burden of Illness Among United States Veteran Treatment-Naive Human Immunodeficiency Virus-Infected Patients.

Li Wang, Ph.D., MBA, M.A.,<sup>1</sup> *Seema Haider, M.Sc.,*<sup>2</sup> Katherine Nedrow, MPH,<sup>3</sup> Richard Chambers, MSPH,<sup>4</sup> Margaret Tawadrous, M.D.,<sup>2</sup> Onur Baser, Ph.D., M.S.,<sup>5</sup> Kit Simpson, DrPH<sup>6</sup>; (1) STATinMED Research, Dallas, TX; (2)Pfizer, Inc.; (3)East Coast Primary Care Inc; (4)Pfizer, Inc; (5)STATinMED Research and The University of Michigan, Ann Arbor, MI; (6)Medical University of South Carolina, Department of Health Leadership and Management College of Health Professions, Charleston, SC

101E. Dolutegravir Treatment Response by Baseline Viral Load and NRTI Backbone in Treatment-Naive HIV-Infected Individuals.

*Joe Eron, M.D.,*<sup>1</sup> Jurgen Rockstroh, M.D.,<sup>2</sup> Anton Pozniak, M.D.,<sup>3</sup> Julian Elliott, M.D.,<sup>4</sup> Catherine B. Small, M.D.,<sup>5</sup> Marc Johnson, M.D.,<sup>6</sup> Clare Brennan, DPT, MSPH,<sup>7</sup> Keith Pappa, Pharm.D.,<sup>7</sup> Robert Cuffe, M.S.<sup>8</sup>; (1)University of North Carolina at Chapel Hill; (2)University of Bonn, Germany; (3)Chelsea and Westminster Hospital, London, UK; (4)The Alfred Hospital, Melbourne, Australia; (5)New York Medical College, Valhalla, NY; (6)Carolinas Medical Center, Charlotte, NC; (7)GlaxoSmithKline; (8)ViiV Healthcare

## Medication Safety

128. Care Transitions Service: A Pharmacy-Driven Medication Reconciliation Program Through the Continuum of Care.

*Jessica Conklin, Pharm.D.,*<sup>1</sup> John Togami, Pharm.D.,<sup>2</sup> Allison Burnett, Pharm.D.,<sup>2</sup> Melanie Dodd, Pharm.D.,<sup>1</sup> Gretchen Ray, Pharm.D.<sup>1</sup>; (1)College of Pharmacy, University of New Mexico, Albuquerque, NM; (2)Department of Pharmacy, University of New Mexico Hospitals, Albuquerque, NM

**Men's Health**

129. Attitudes and Perceptions of a Rural Mississippi Delta Population Toward Prostate Cancer Treatments.

*Justin J. Sherman, MCS, Pharm.D.,<sup>1</sup> Laurie Warrington, Pharm.D., BC-ACP,<sup>2</sup> Daniel M. Riche, Pharm.D., BCPS, CDE<sup>2</sup>; (1)The University of Mississippi School of Pharmacy, Jackson, MS; (2) University of Mississippi School of Pharmacy, Jackson, MS*

**Nephrology**

130E. Accuracy of Urine Collection Methods Compared to Measured GFR in Adults with Liver Disease.

*Joanna Q. Hudson, Pharm.D., FCCP, FASN, BCPS,<sup>1</sup> Asif Siddiqui, M.D.<sup>2</sup>; (1)University of Tennessee, Memphis, TN; (2)College of Medicine, University of Tennessee, Memphis, TN*

131E. Sodium-Dependent Glucose Co-transporter 2 (SGLT2) Inhibition Prevents the Development of Nephropathy in Diabetic Mice.

*Gerald Shiohita, Pharm.D.,<sup>1</sup> Liru Qiu, M.D.,<sup>2</sup> Xiaoxin Wang, Ph.D.,<sup>2</sup> Veronica Hogg-Cornejo, B.S.,<sup>2</sup> Cherelle Parker, B.S.,<sup>2</sup> Jimmy Ren, Ph.D.,<sup>3</sup> Yin Liang, M.D., Ph.D.,<sup>4</sup> Moshe Levi, M.D.<sup>2</sup>; (1) Medical Affairs, Janssen Scientific Affairs (Janssen Pharmaceuticals), Boulder, CO; (2)Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Aurora, CO; (3)Department of Medical Affairs, Janssen Pharmaceuticals, Raritan, NJ; (4)Department of Research and Development, Janssen Pharmaceuticals, Raritan, NJ*

132E. Trimethoprim (TMP)/Sulfamethoxazole (SMX) Loss in Modeled Continuous Renal Replacement Therapy (CRRT).

*A. Mary Vilay, Pharm.D.,<sup>1</sup> Jacob Kesner, Pharm.D. Candidate,<sup>1</sup> J. Michael Yardman-Frank, B.S. Candidate,<sup>1</sup> Ronald Schrader, Ph.D.,<sup>1</sup> Renee Mercier, Pharm.D.,<sup>1</sup> Dean Argyres, M.S.,<sup>2</sup> Craig Wong, M.D., MPH<sup>1</sup>; (1)University of New Mexico, Albuquerque, NM; (2)VA Cooperative Studies Program, Albuquerque, NM*

**Pain Management/Analgesia**

137. Lubiprostone for Treatment of Opioid-Induced Constipation Does Not Interfere with Opioid Analgesic Effects in Patients with Non-cancer Pain.

*Egilius L.H. Spierings, M.D., Ph.D.,<sup>1</sup> Taryn Joswick, B.S., PMP,<sup>2</sup> Shadreck Mareya, Ph.D.,<sup>2</sup> Yijun Sun, Ph.D.,<sup>2</sup> Ryuji Ueno, M.D., Ph.D.<sup>3</sup>; (1)Headache & Face Pain Program, Tufts Medical Center, and Craniofacial Pain Center, Tufts University School of Dental Medicine, Watertown, MA; (2)Sucampo Pharma Americas, LLC, Bethesda, MD; (3)Sucampo AG, Zug, Switzerland*

138. Evaluation of the Impact of a Pharmacist-Provided Non-malignant Chronic Opioid Management Education Program to Physicians in a Primary Care Practice Setting.

*Rebecca Bragg, Pharm.D., Amy M. Drew, Pharm.D., BCPS, Jamie M. Pitlick, Pharm.D., BCPS; St. Louis College of Pharmacy, St. Louis, MO*

139E. Treatment of Episodic Tension-Type Headache with a Novel Formulation of Ibuprofen Sodium.

*Elias Packman, ScD,<sup>1</sup> Rina Leyva, M.S.,<sup>2</sup> David Kellstein, Ph.D.<sup>2</sup>; (1)Institute for Applied Pharmaceutical Research, Philadelphia, PA; (2)Pfizer Consumer Healthcare, Madison, NJ*

140E. A Novel Formulation of Ibuprofen Sodium Is Absorbed Faster than Standard Ibuprofen Tablets.

*Thomas Legg, D.O.,<sup>1</sup> Rina Leyva, M.S.,<sup>2</sup> David Kellstein, Ph.D.<sup>2</sup>; (1)CoxHealth, Springfield, MO; (2)Pfizer Consumer Healthcare, Madison, NJ*

141E. A Novel Formulation of Ibuprofen Sodium Has a Faster Onset of Analgesia than Standard Ibuprofen Tablets in the Treatment of Postoperative Dental Pain.

Patrick Brain, DDS,<sup>1</sup> Rina Leyva, M.S.,<sup>2</sup> David Kellstein, Ph.D.<sup>2</sup>; (1)Jean Brown Research, Salt Lake City, UT; (2)Pfizer Consumer Healthcare, Madison, NJ

142. Medication Use Patterns Among Patients with Chronic Low Back Pain Taking Chronic Opioids.

Margaret L. Wallace, Pharm.D., BCACP,<sup>1</sup> Aleksandra Zgierska, M.D., Ph.D.,<sup>2</sup> Jennifer Cox, B.S.,<sup>2</sup> Cindy Burzinski, M.S.,<sup>2</sup> Iliya Amaza, M.D.,<sup>2</sup> David Rabago, M.D.<sup>2</sup>; (1)Department of Family Medicine, University of Wisconsin, Madison, WI; (2)University of Wisconsin

143. An Analysis of Hospital Consumer Assessment of Healthcare Providers and Systems Pain Scores on an Internal Medicine Service.

William Wilkie, Pharm.D.,<sup>1</sup> George Davis, Pharm.D.,<sup>1</sup> Kristy Deep, M.D.,<sup>2</sup> Sara Brouse, Pharm.D.<sup>1</sup>; (1)Department of Pharmacy Services, UK HealthCare, Lexington, KY; (2)Department of Internal Medicine Services, UK HealthCare, Lexington, KY

### **Pediatrics**

144. Gaining a Unit-Specific Understanding for the Need of Fungal Prophylaxis in the Intensive Care Nursery.

Tracy Sandritter, Pharm.D.,<sup>1</sup> Alexandra Oschman, Pharm.D.<sup>2</sup>; (1)Clinical Pharmacology/Toxicology, Children's Mercy Hospitals and Clinics, Kansas City, MO; (2)Children's Mercy Hospital and Clinics, Kansas City, MO

145. Metabolic Monitoring in Pediatric Patients Receiving Second-Generation Antipsychotics.

Yardlee S. Kauffman, Pharm.D., MPH,<sup>1</sup> Sheila Botts, Pharm.D.,<sup>2</sup> Kerri Gaughan, Pharm.D.,<sup>2</sup> Thomas Delate, Ph.D., M.S.<sup>2</sup>; (1)Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO; (2)Kaiser Permanente Colorado, Aurora, CO

146. Medication Dosing Alert Rates at a Pediatric Institution.

Jeremy S. Stultz, Pharm.D., Milap C. Nahata, Pharm.D., M.S.; Ohio State University College of Pharmacy, Columbus, OH

148. Ciprofloxacin for the Treatment of Non-resolving Pneumonia in a Tertiary Care Pediatric Hospital.

Mohammed Habil Sr, M.S.; Department of Pharmacy, Al-Rantisy Specialized Pediatric Hospital, Gaza, Palestine., Gaza, Palestine

### **Pharmacoeconomics/Outcomes**

149. Economical Analysis of Pharmacy Intervention in the Intensive Care Units in a Medical Center in Taiwan.

Chun-Nan Kuo, Master, Pi-Yu Lee, Master; Taipei Medical University-WanFang Hospital

150. Cost-effectiveness of Rivaroxaban Compared with Enoxaparin Plus a Vitamin K Antagonist for the Treatment of Venous Thromboembolism.

Patrick Lefebvre, M.A.,<sup>1</sup> Craig I. Coleman, Pharm.D.,<sup>2</sup> Brahim Bookhart, MBA, MPH,<sup>3</sup> Si-Tien Wang, M.Sc.,<sup>4</sup> Samir H. Mody, Pharm.D., MBA,<sup>3</sup> Kevin Tran, MPH,<sup>4</sup> Daisy Zhuo, B.A.,<sup>4</sup> Lynn Huynh, MPH, MBA, DrPH,<sup>4</sup> Edith A. Nutescu, Pharm.D.<sup>5</sup>; (1)Groupe d'Analyse, Ltée., Montreal, QC, Canada; (2)University of Connecticut, Hartford, CT; (3)Janssen Scientific Affairs, LLC, Raritan, NJ; (4)Analysis Group, Boston, MA; (5)University of Illinois at Chicago College of Pharmacy, Chicago, IL



151. Tracking Thrombosis and Pain Metrics in a Status-post Orthopedic Surgical Population: Results from a Participating Institution in the Surgical Outcomes Project (SOS).

*Nick Carris, Pharm.D.*,<sup>1</sup> Eric Dietrich, Pharm.D., BCPS,<sup>2</sup> Amy Schultz, Pharm.D.,<sup>3</sup> Joseph Alessandrini, Pharm.D.,<sup>4</sup> Lew Summers, B.S.,<sup>4</sup> John Gums, Pharm.D., FCCP;<sup>2</sup> (1)TriStar Centennial Medical Center, Nashville, TN; (2)University of Florida College of Pharmacy, Gainesville, FL; (3)East Alabama Medical Center, Opelika, AL; (4)Inspira Medical Center Vineland, Vineland, NJ

152. Cost-effectiveness Analysis of Probiotic Adjunct Therapy in Reducing the Incidence and Duration of *Clostridium difficile*-Associated Diarrhea in Hospitalized Older Adults.

*Bich Ngoc Hoang, Pharm.D. Candidate*,<sup>1</sup> Paul Norris, Pharm.D. Candidate,<sup>2</sup> Shivan Acharya, Pharm.D. Candidate,<sup>2</sup> Adrienne Kowcz, Pharm.D. Candidate,<sup>2</sup> Austin Kang, Pharm.D. Candidate;<sup>2</sup> (1)School of Pharmacy, Northeastern University, Boston, MA; (2) Northeastern University

153. Estimated Cost Savings Associated with A1c Reductions Among Insulin-Treated Patients in a Large U.S. Commercial Health Plan.

*Michael Grabner, Ph.D.*,<sup>1</sup> Scott Abbott, M.S.,<sup>2</sup> Matthew Nguyen, Pharm.D.,<sup>2</sup> Ralph Quimbo, M.A.<sup>1</sup>; (1)HealthCore, Inc., Wilmington, DE; (2)Valeritas, Inc., Bridgewater, NJ

154. Risk of Type 2 Diabetes Associated with Statin Therapy Among Elderly Patients – A Nested Case-Control Study.

Manasi Datar, M.S.,<sup>1</sup> Yi Yang, M.D., Ph.D.,<sup>1</sup> *Matthew Strum, Pharm.D., BCACP, CDE*,<sup>2</sup> John Bentley, Ph.D., MBA, B.S.,<sup>1</sup> Benjamin Banahan III, Ph.D.<sup>3</sup>; (1)Department of Pharmacy Administration, University of Mississippi School of Pharmacy, University, MS; (2)Department of Pharmacy Practice, University of Mississippi School of Pharmacy, University, MS; (3)Center for Pharmaceutical Marketing and Management, University of Mississippi School of Pharmacy, University, MS

156. Monotherapy of Commonly Used Anti-hyperglycemic Agents (AHAs) for the Treatment of Type 2 Diabetes Mellitus (T2DM): Patient Characteristics and Time to Addition of Subsequent Therapy (Augmentation).

Silas Martin, M.S.,<sup>1</sup> James Burke, Ph.D.,<sup>2</sup> Cheryl Neslusan, Ph.D.,<sup>3</sup> Jonathan Johnson, M.S.,<sup>2</sup> *Robert Bailey, M.D.*<sup>4</sup>; (1)Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ; (2)Health Economics and Outcomes Research, OptumInsight, Eden Prairie, MN; (3)Global Strategic Marketing and Market Access, Janssen Global Services, LLC, Raritan, NJ; (4)Janssen Scientific Affairs, LLC

157. Outcomes of Systematic Anticoagulation Management in Pharmacist- vs. Nurse-Specialized Clinics.

*Beenish Manzoor, MPH*,<sup>1</sup> Adriana Bautista, M.D., MPH,<sup>2</sup> Thomas Stamos, M.D.,<sup>3</sup> Weihua Gao, M.S.,<sup>4</sup> Edith Nutescu, Pharm.D.<sup>5</sup>; (1)Department of Pharmacy Systems, Operations, and Policy, University of Illinois at Chicago, College of Pharmacy, Chicago, IL; (2)University of Illinois at Chicago; (3)University of Illinois at Chicago, Section of Cardiology, Department of Medicine, Chicago, IL; (4)University of Illinois at Chicago, CCTS; (5)University of Illinois at Chicago College of Pharmacy, Department of Pharmacy Practice, Chicago, IL

### Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery

167E. Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients.

*Ashley W. Sturm, Pharm.D., BCPS*,<sup>1</sup> Nichole Allen, Pharm.D., BCPS,<sup>1</sup> Kelly D. Rafferty, Pharm.D., BCPS,<sup>1</sup> Douglas N. Fish, Pharm.D., BCPS,<sup>2</sup> Eric Toschlog, M.D., FCCS,<sup>1</sup> Mark Newell, M.D.,<sup>1</sup> Brett Waibel, M.D.<sup>1</sup>; (1)Vidant Medical Center, Greenville, NC; (2)University of Colorado Anschutz Medical Campus, Aurora, CO

168. Dabigatran Etexilata Is Metabolized to its Active Metabolite by Carboxylesterases. *S. Casey Laizure, Pharm.D., Zheyi Hu, Ph.D., Vanessa Herring, B.S., Robert B. Parker, Pharm.D.; University of Tennessee Department of Clinical Pharmacy, Memphis, TN*

169. Dabigatran Etexilata Metabolism Is Not Affected by Alcohol, a Known Inhibitor of Carboxylesterase Activity.

*Robert B. Parker, Pharm.D., Zheyi Hu, Ph.D., S. Casey Laizure, Pharm.D.; University of Tennessee Department of Clinical Pharmacy, Memphis, TN*

170. Renal *N*-Acetyltransferase (NAT) Expression and Activity in HK-2 Cells.

*Ellen Huang, B.S.,<sup>1</sup> Aila Spiegel, Pharm.D.,<sup>1</sup> Hui Yang, Ph.D.,<sup>2</sup> Linhao Li, Ph.D.,<sup>2</sup> Thomas Dowling, Pharm.D., Ph.D.<sup>3</sup>; (1)University of Maryland; (2)Department of Pharmaceutical Sciences, University of Maryland; (3)Department of Pharmacy Practice and Science, University of Maryland, Baltimore, MD*

171. Impact of Prolonged Magnesium Infusion on Serum Magnesium Level.

*Michelle Nadeau, Pharm.D.,<sup>1</sup> Rachel Eycler, Pharm.D., BCPS,<sup>2</sup> Eric M. Tichy, Pharm.D., BCPS<sup>3</sup>; (1) Department of Pharmacy, Yale-New Haven Hospital, New Haven, CT; (2)School of Pharmacy, University of Connecticut, Storrs, CT; (3)Yale-New Haven Hospital, New Haven, CT*

172. Pharmacokinetics and Pharmacodynamics of Long-term Tocilizumab Therapy in Patients with Systemic Juvenile Idiopathic Arthritis.

*Fabrizio De Benedetti, M.D., Ph.D.,<sup>1</sup> Hermine Brunner, M.D., M.Sc., MBA,<sup>2</sup> Scott Fettner, B.A.,<sup>3</sup> Caroline Keane, Ph.D.,<sup>4</sup> Clare Devlin, Ph.D.,<sup>4</sup> Jianmei Wang, Ph.D.,<sup>4</sup> Nicolino Ruperto, M.D., MPH<sup>5</sup>; (1)IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; (2)Cincinnati Children's Hospital Medical Center; PRCSG, Cincinnati, OH; (3)Hoffmann-La Roche, Nutley, NJ; (4) Roche, Welwyn Garden City, United Kingdom; (5)PRINTO, Genoa, Italy*

173. Pharmacokinetics and Pharmacodynamics of Long-term Tocilizumab Therapy in Polyarticular Juvenile Idiopathic Arthritis.

*Scott Fettner, B.A.,<sup>1</sup> Peng Lu, M.D., Ph.D.,<sup>1</sup> Joy Hsu, Ph.D.,<sup>1</sup> Caroline Keane, Ph.D.,<sup>2</sup> Jianmei Wang, Ph.D.,<sup>2</sup> Nicolino Ruperto, M.D., MPH,<sup>3</sup> Fabrizio De Benedetti, M.D., Ph.D.,<sup>4</sup> Hermine Brunner, M.D., M.Sc., MBA<sup>5</sup>; (1)Hoffmann-La Roche, Nutley, NJ; (2)Roche, Welwyn Garden City, United Kingdom; (3)PRINTO, Genoa, Italy; (4)IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy; (5)Cincinnati Children's Hospital Medical Center; PRCSG, Cincinnati, OH*

174. Development of a Prodrug Database.

*Shin-Yu Lee, Pharm.D.,<sup>1</sup> S. Joshua Swamidass, M.D., Ph.D.,<sup>2</sup> Anne Rogers, Pharm.D. Candidate 2014,<sup>1</sup> Margaret Riley, Pharm.D. Candidate 2014<sup>1</sup>; (1)Pharmacy Practice Division, St. Louis College of Pharmacy, St. Louis, MO; (2)Department of Immunology and Pathology, Division of Laboratory and Genomic Medicine (LGM), Washington University, MO*

## **Pulmonary**

179. Examining Appropriate Inhaler Usage Among Indigent Patients. *Jonathan Newsome, Pharm.D.; Pharmacy Practice, South College School of Pharmacy, Knoxville, TN*

180. Evaluation of a Therapeutic Interchange of Scheduled Ipratropium to Tiotropium for Use in Hospitalized Patients with Chronic Obstructive Pulmonary Disease.

*William Ngo, Pharm.D.,<sup>1</sup> Katie Buehler, Pharm.D.,<sup>2</sup> Nicholas Hampton, Pharm.D.,<sup>3</sup> Michael Daly, Pharm.D., MSCI<sup>2</sup>; (1)Department of Pharmacy, Missouri Baptist Medical Center, St. Louis, MO; (2)St. Louis College of Pharmacy, St. Louis, MO; (3)BJC Center for Clinical Excellence, St. Louis, MO*

**Transplantation/Immunology**

201. Analysis of Risk Factors Affecting Medication Knowledge After Transplantation.

Chelsea Sammons, Pharm.D., *Christina T. Doligalski, Pharm.D., BCPS*; Tampa General Hospital, Tampa, FL

**CLINICAL PHARMACY FORUM**

These abstracts describe the delivery, development, justification, or documentation of an innovative clinical pharmacy service; they may be descriptive only and need not contain an evaluative component.

**ADR/Drug Interactions**

203E. Identifying High-Risk Patients for Pain Management Strategies Aimed at Reducing Postsurgical Opioid-Related Adverse Events.

*Kathy Nipper-Johnson, RN, BSN, CCM*,<sup>1</sup> Harold Minkowitz, M.D.,<sup>2</sup> Richard Scranton, M.D.,<sup>3</sup> Manan Shah, MPH,<sup>4</sup> Aditya Raju, M.S., B(Pharm),<sup>4</sup> Stephen K. Gruschkus, Ph.D., MPH<sup>4</sup>; (1)Case Management, Memorial Hermann Memorial City Medical Center, Houston, TX; (2)Memorial Hermann Memorial City Medical Center, Houston, TX; (3)Pacira Pharmaceuticals, Inc., Parsippany, NJ; (4)Xcenda® AmerisourceBergen Consulting Services, Palm Harbor, FL

**Adult Medicine**

204. Taking Control of Controlled Substance Prescribing in an Academic Family Practice Center.

*Cari Brackett, Pharm.D., B.S.*,<sup>1</sup> Becky Wilkins, B.S.,<sup>2</sup> Nicholas Kahl, RN, MSN,<sup>3</sup> William Buoni, M.D.<sup>2</sup>; (1)Division of Pharmacy Practice and Administration, Ohio State University College of Pharmacy, Columbus, OH; (2)The Ohio State University Wexner Medical Center, Columbus, OH; (3)Rardin Family Practice Center, The Ohio State University Wexner Medical Center, Columbus, OH

205. Medication Management to IMprove Post Acute Care Transfer (IMPACT).

*Erin Neal, Pharm.D., BCPS*, Amy Myers, Pharm.D., BCPS, Patricia B. Miller, Pharm.D.; Vanderbilt University Medical Center, Nashville, TN

206. Reduction in Missed Doses of Warfarin Through Use of an Order Reminder in the EPIC Electronic Medical Record.

*Maura Wychowski, Pharm.D., BCPS*; Department of Pharmacy, Rochester General Hospital, Rochester, NY

**Ambulatory Care**

207. Factors Influencing Enrollment in the Medication Therapy Management Clinic (MTMC) at an Academic Ambulatory Care Clinic.

*Mansi Shah, Pharm.D., BCACP*,<sup>1</sup> Jessica Tilton, Pharm.D., BCACP,<sup>2</sup> Shiyun Kim, Pharm.D., CDE<sup>2</sup>; (1)Pharmacy Practice, University of Illinois at Chicago, Chicago, IL; (2)University of Illinois at Chicago, Chicago, IL

208. Promoting Safe Use of Medications: Providing Medication Education to Seniors Receiving Meals on Wheels.

*Kristina Ward, Pharm.D., B.S., BCPS*, Lisa Cohen, Pharm.D., CDE; Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, RI

209. Evaluation of a Pharmacist's Impact in a University-Based Wellness Clinic: A Pilot Study. *Angela H. Pegram, Pharm.D., BCPS, CDE*, Sabrina W. Cole, Pharm.D., BCPS; Wingate University School of Pharmacy, Wingate, NC

210. Implementing Clinical Pharmacy Services Within a Multidisciplinary Bariatric Surgery Team.

*Taya M. Staples, Pharm.D., BCPS*, Sara Griesbach, Pharm.D., BCPS, BCACP; Marshfield Clinic, Marshfield, WI

211. Highlighting the Work of the ACCP Ambulatory Care PRN in 2012–2013.

*Catherine A. Bourg, Pharm.D., BCPS, BCACP*<sup>1</sup> Stefanie Nigro, Pharm.D., BCACP, BC-ADM,<sup>2</sup> Marissa E. Quinones, Pharm.D., CDE,<sup>3</sup> Maria M. Thurston, Pharm.D., BCPS,<sup>4</sup> Emily McCoy Armstrong, Pharm.D., BCACP,<sup>5</sup> Brian K. Irons, Pharm.D., FCCP, BCPS, BCACP, BC-ADM<sup>6</sup>; (1)University of Georgia College of Pharmacy, Athens, GA; (2)University of Connecticut – School of Pharmacy, Storrs, CT; (3)Parkland, Dallas, TX; (4)Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, Atlanta, GA; (5)Auburn University Harrison School of Pharmacy Mobile Campus, Mobile, AL; (6)TTUHSC School of Pharmacy, Lubbock, TX

212. Evaluating a Pharmacist-Managed 24-Hour Ambulatory Blood Pressure Monitoring Service in the Primary Care Setting.

*Kristina Susic, Pharm.D.*,<sup>1</sup> *Peter Koval, Pharm.D.*<sup>2</sup>; (1)Family Medicine, Moses H. Cone Hospital, Greensboro, NC; (2)Family Medicine, Moses Cone Family Medicine, Greensboro, NC

213. Upper Extremity Deep Vein Thrombosis (UEDVT) in a Sickle Cell Subset Population: A Retrospective Cohort Evaluation at a University Teaching Hospital Antithrombosis Clinic.

*Rebecca H. Stone, Pharm.D.*, Adam P. Bress, Pharm.D., Edith A. Nutescu, Pharm.D., Nancy L. Shapiro, Pharm.D.; University of Illinois at Chicago College of Pharmacy, Chicago, IL

214. Pharmacist Integration in Pre-visit Planning in the Medical Home.

*Megan Mormann, Pharm.D.*,<sup>1</sup> *James D. Hoehns, Pharm.D., FCCP, BCPS*<sup>2</sup>; (1)Northeast Iowa Family Practice Center & Waverly Health Center, Waterloo, IA; (2)University of Iowa College of Pharmacy and Northeast Iowa Family Practice Center, Waterloo, IA

215E. Management of Medication-Related Problems at Transitions of Care by Medical Home Pharmacists for a Safety Net Population.

*Grace Kim, Pharm.D.*, Mimi Lou, M.S., Steven Chen, Pharm.D., FASHP, FCSHP; School of Pharmacy, University of Southern California, Los Angeles, CA

216. Implementation of a Clinical Pharmacist-Directed Hospital Discharge Service to Improve Transitions in Care.

*Anita Sharma, Pharm.D.*, Chrystian R. Pereira, Pharm.D.; University of Minnesota College of Pharmacy, Minneapolis, MN

217. Outcomes of Ambulatory Medication Reconciliation in a Geriatric Patient-Centered Medical Home.

*Victoria Liu, Pharm.D.*,<sup>1</sup> Bibban Bant Deol, M.D.,<sup>2</sup> Ann Balarezo, CNP,<sup>3</sup> David Trupiano, Pharm.D.,<sup>1</sup> Candice L. Garwood, Pharm.D.<sup>4</sup>; (1)Department of Pharmacy Services, Detroit Medical Center Harper University Hospital, Detroit, MI; (2)Department of Internal Medicine/Geriatrics, Wayne State University School of Medicine, Detroit; (3)Rosa Parks Wellness Institute for Senior Health, Detroit Medical Center Geriatric Center of Excellence, Detroit, MI; (4) Department of Pharmacy Practice, Wayne State University, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI

218. The Impact of Pharmacist-Physician Collaborative Diabetes Care in a Medically Underserved Population.

*Jennifer L. Rosselli, Pharm.D.,<sup>1</sup> Christina Ley, Pharm.D., J. Christopher Lynch, Pharm.D.<sup>1</sup>;* (1) Southern Illinois University Edwardsville School of Pharmacy, Edwardsville, IL

### Critical Care

225F. Implementation and Evaluation of a New Sedation, Analgesia, and Delirium Order Set in a Large Community Hospital.

*Jonathan D. Edwards, Pharm.D.,<sup>1</sup> Adam Sawyer, Pharm.D.,<sup>2</sup> Katie Sims, Pharm.D.,<sup>2</sup> Edward Eiland III, Pharm.D., MBA<sup>3</sup>;* (1)Department of Pharmacy, Huntsville Hospital, Huntsville, AL; (2) Huntsville Hospital, Huntsville, AL; (3)Department of Pharmacy, Huntsville Hospital System, Huntsville, AL

### Gastroenterology

237. Corticosteroid Avoidance in Patients with Crohn's Disease Who Are Newly Initiated to Therapy with an Anti-TNF Agent versus Azathioprine.

*Sunanda Kane, M.D., MSPH, FACG,<sup>1</sup> Tanna Hassig, Pharm.D., BCPS,<sup>2</sup> Phyllis Malpas, M.A., RN, CGRN,<sup>2</sup> KellyAnne Pennington, RN, BSN, CCRN,<sup>2</sup> Teak Smith, RN, BSN,<sup>2</sup> Rachel Velvet Hicks, RN,<sup>2</sup> Merriman Dowdle, M.S., PA-C,<sup>2</sup> Srihari Jaganathan, M.S.,<sup>3</sup> Sara Horst, M.D., MPH,<sup>4</sup> David A. Schwartz, M.D.<sup>4</sup>;* (1)Mayo Clinic, Rochester, MN; (2)Medical University of South Carolina, Charleston, SC; (3)UCB Pharma, Smyrna, GA; (4)Vanderbilt University Medical Center, Nashville, TN

238. Corticosteroid Taper in Crohn's Disease Patients (PRECISE 2 trial): An Important Role for Pharmacists.

*Tanna Hassig, Pharm.D., BCPS,<sup>1</sup> Cem Kayhan, M.D.,<sup>2</sup> Bosny Pierre-Louis, DrPH,<sup>2</sup> Phyllis Malpas, M.A., RN, CGRN,<sup>1</sup> KellyAnne Pennington, RN, BSN, CCRN,<sup>1</sup> Teak Smith, RN, BSN,<sup>1</sup> Rachel Velvet Hicks, RN,<sup>1</sup> Merriman Dowdle, M.S., PA-C<sup>1</sup>;* (1)Medical University of South Carolina, Charleston, SC; (2)UCB Pharma, Raleigh, NC

### Health Services Research

241. The Effectiveness of Pharmacist-Involved Collaborative Care Model in the Management of Patients with Diabetes: A Million Dollar Initiative in Asia.

*Joyce Lee, Pharm.D., BCPS, BCACP<sup>1</sup> Yu Ko, Ph.D.,<sup>1</sup> Melanie Siaw, BSc(Pharm)(Hons),<sup>1</sup> Daniel Malone, RPh, Ph.D.<sup>2</sup>;* (1)Department of Pharmacy, Faculty of Science at National University of Singapore, Singapore; (2)Department of Pharmacy Practice and Science, The University of Arizona, Tucson, AZ

### Managed Care

245. Economic Analysis of a Primary Care Clinical Pharmacy Service on Post-fracture Care in Postmenopausal Women.

*Adriane N. Irwin, Pharm.D., M.S.,<sup>1</sup> Rachel M.F. Heilmann, Pharm.D.,<sup>2</sup> Sarah J. Billups, Pharm.D.<sup>1</sup>;* (1)Kaiser Permanente Colorado, Aurora, CO; (2)Kaiser Permanente Colorado, Denver, CO

### Medication Safety

247. Use of an Interactive Magnesium Allergy Listing in the Electronic Medical Record to Prevent Magnesium-Induced Myasthenia Crisis.

*Margaret Verrico, BS(Pharm),<sup>1</sup> Richard Simmons, M.D.,<sup>2</sup> David Lacomis, M.D.<sup>2</sup>;* (1)Department of Pharmacy/School of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA; (2) University of Pittsburgh Medical Center, Pittsburgh, PA

248. Evaluation of Azithromycin Use in High-Risk Patients: Response to the FDA Drug Risk Communication.

*Zhe Han, Pharm.D.,* Natasha N. Pettit, Pharm.D., Benjamin D. Brielmaier, Pharm.D.; University of Chicago Medicine, Chicago, IL

249. Pharmacist- versus Physician-Conducted Medication Reconciliation on an Internal Medicine Service at an Urban Teaching Hospital.

*Michael J. Gonyeau, Pharm.D., BS(Pharm), FCCP, BCPS,<sup>1</sup>* Emily Heath, Pharm.D., B.S.<sup>2</sup>; (1) Northeastern University School of Pharmacy, Boston, MA; (2) Sarasota, FL

250. Creation and Implementation of a Web-Based Home-Grown Pharmacy Intervention System Using Microsoft SharePoint®.

*Adam B. Woolley, Pharm.D., BCPS,<sup>1</sup>* Maria Scarlatos, B.S.,<sup>1</sup> Shawn Saunders, Pharm.D.<sup>2</sup>; (1) School of Pharmacy, Northeastern University, Boston, MA; (2) VA Boston Healthcare System, West Roxbury, MA

251. Innovative Use of Prescription Cancellation Data to Improve Patient Safety and Efficiency Within a Mail Order Pharmacy.

*Carrie Nolan, Pharm.D.,* George Dooling, Pharm.D., Gia Leonetti, Pharm.D. Candidate, Michael Sutherland, Pharm.D.; VA SW CMOP, Tucson, AZ

252. Assessing the Accuracy and Quality of Medication History Collection: Effect of Implementation of Electronic Health Record.

*Kena Lanham, Pharm.D., BCPS,<sup>1</sup>* Lindsay Saum, Pharm.D., BCPS, CGP<sup>2</sup> David Reeves, Pharm.D., BCOP, Colleen Scherer, Pharm.D., MPA, BCPS, Beth Johnston, Pharm.D., BCPS,<sup>1</sup> Anthony Antonopoulos, RPh, MBA, Suellyn Sorensen, Pharm.D., BCPS<sup>1</sup>; (1) Department of Pharmacy, Saint Vincent Hospital, Indianapolis, IN; (2) Department of Pharmacy Practice, Butler University, Indianapolis, IN

253. The Positive Impact of a Med Rec ED Pharmacist on Medication Management in Patients Admitted to a Hospitalists' Service.

*Anthony Intintoli, M.D., FACP, FHM,<sup>1</sup>* Anna Dushenkov, Pharm.D., BCPS,<sup>2</sup> Sanu Koshy-Varghese, Pharm.D.,<sup>3</sup> William Hendricks, RPh,<sup>4</sup> Jack Mateyunas, RPh<sup>5</sup>; (1) Huntington Hospital NSLJ HS; (2) Pharmacy, Huntington Hospital NSLJ HS; (3) Emergency Department/Pharmacy, Huntington Hospital NSLJ HS; (4) Pharmacy, Huntington Hospital NSLJ HS; (5) Huntington Hospital NSLJ HS

### **Pharmacoeconomics/Outcomes**

257. Erythropoietin-Stimulating Agent Use During Transitions in Care.

*Jeff Hurren, Pharm.D.,<sup>1</sup>* Michael Palmer, RPh,<sup>2</sup> Anthony Elias, Pharm.D.,<sup>3</sup> Michelle Dehoorne-Smith, Pharm.D.<sup>2</sup>; (1) Department of Pharmacy Services, St. John Hospital & Medical Center, Detroit, MI; (2) St. John Hospital & Medical Center, Detroit, MI; (3) University of Michigan, Ann Arbor, MI

258E. Impact of Regular Molecular Monitoring on Tyrosine Kinase Inhibitor Therapy Adherence in Chronic Myelogenous Leukemia in the Chronic Phase.

*Annie Guérin, M.Sc.,<sup>1</sup>* Lei Chen, M.D., Ph.D.,<sup>2</sup> Eric Q. Wu, Ph.D.,<sup>1</sup> Katherine Dea, M.Sc.,<sup>1</sup> Stuart L. Goldberg, M.D.<sup>3</sup>; (1) Analysis Group Inc., Boston, MA; (2) Oncology US CD & MA, Novartis Pharmaceuticals Corp., East Hanover, NJ; (3) Division of Leukemia, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ

259E. Reducing Total Healthcare Costs by Shifting to Outpatient (OP) Settings of Care for the Management of Gram + Acute Bacterial Skin and Skin Structure Infections (ABSSSIs).  
*Alexandra Khachatryan, MPH,<sup>1</sup>* Varun Ektare, MPH,<sup>1</sup> Mei Xue, MBA,<sup>1</sup> Michael W. Dunne,

M.D.,<sup>2</sup> *Kenneth E. Johnson, Pharm.D.*,<sup>3</sup> Jennifer M. Stephens, Pharm.D.<sup>1</sup>; (1)Pharmerit International, Bethesda, MD; (2)Durata Therapeutics, Inc., Branford, CT; (3)Corporate Medical Affairs, Durata Therapeutics, Inc., Chicago, IL

260. Cost Trade-off Analysis of Bupivacaine Liposome Injectable Suspension in a Community Hospital Setting.

*Jodie Pepin, Pharm.D.*,<sup>1</sup> Robert Wright, Pharm.D.<sup>2</sup>; (1)Department of Pharmacy, Seton Medical Center Williamson, Round Rock, TX; (2)Department of Pharmacy, Seton Medical Center Austin, Austin, TX

### **Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**

263E. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Weekly Doses of Intravenous Dalbavancin in Healthy Subjects.

*Michael W. Dunne, M.D.*,<sup>1</sup> Craig Sprenger, M.D.,<sup>2</sup> Susan Moriarty, M.D.<sup>1</sup>; (1)Durata Therapeutics, Inc., Branford, CT; (2)PRACS, Fargo, ND

### **Pulmonary**

265. Saxagliptin as Add-on to Metformin + Sulfonyleurea in Patients with Type 2 Diabetes: Outcomes Stratified by Baseline Glycated Hemoglobin and Patient Characteristics.

*Jodey Given, Ph.D.*

### **LATE BREAKERS**

These papers describe original research in therapeutics, pharmacokinetics, pharmacodynamics, pharmacoeconomics, and pharmacoepidemiology.

#### **Adult Medicine**

383. Medication Discrepancies Captured During Post-discharge Phone Calls to Patients on the Hospitalist Service at a Large Academic Hospital.

*Tran Tran, Pharm.D., BCPS*,<sup>1</sup> Hanlin Li, Pharm.D. Candidate,<sup>2</sup> Jennifer Miao, Pharm.D. Candidate<sup>2</sup>; (1)College of Pharmacy and Health Sciences, St. John's University, NY; (2)NY-Presbyterian Hospital-Columbia University Medical Center, New York, NY

#### **Ambulatory Care**

384. Evaluation of the Measurement of Vitamin D Levels and Risk Factors Associated with Deficiency at a Veterans Affairs Medical Center.

*Kaitlyn Adams, Pharm.D.*, Jim Lichauer, Pharm.D., Crystal Burkhardt, Pharm.D.; Pharmacy Practice Residency Program, Kansas City VA Medical Center, Kansas City, MO

#### **Education/Training**

385. Evaluation of Implementation and Assessment of PCOA Data as Part of a SEP at a State College of Pharmacy.

Justine S. Gortney, Pharm.D., BCPS,<sup>1</sup> *Francine Salinitri, Pharm.D.*,<sup>2</sup> Lynette R. Moser, Pharm.D.,<sup>3</sup> Richard Lucarotti, Pharm.D.,<sup>2</sup> Richard Slaughter, M.S., BS(Pharm)<sup>4</sup>; (1)Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; (2)Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; (3) Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI; (4)Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI

### **Hematology/Anticoagulation**

386. A Matched Case-Control Evaluation of the Risk of Upper Extremity Deep Vein Thrombosis in Patients with Peripherally Inserted Central Catheters.

*Julia L. Reffert, Pharm.D., BCPS,<sup>1</sup> Winter J. Smith, Pharm.D., BCPS,<sup>1</sup> Matthew L. Bird, Pharm.D., BCPS,<sup>1</sup> Donald L. Harrison, Ph.D., FAPhA,<sup>1</sup> Omar L. Esponda, M.D.,<sup>2</sup> Suman W. Rathbun, M.D., M.S., FACP, RVT<sup>2</sup>; (1)University of Oklahoma Health Sciences Center, College of Pharmacy, Oklahoma City, OK; (2)University of Oklahoma Health Sciences Center, College of Medicine, Oklahoma City, OK*

### **Infectious Diseases**

387. Influenza Susceptibility to Neuraminidase Inhibitors.

*Scot E. Walker, Pharm.D., M.S., BCPS, BCACP; Facts & Comparisons/Lexicomp/Medi-Span, St. Louis, MO*

### **Neurology**

388. Uncontrolled Seizures and Bone Health Among Adult Epilepsy Patients.

*Mikiko Yamada, Pharm.D., M.S.,<sup>1</sup> Timothy Welty, Pharm.D.,<sup>2</sup> Sue Min Lai, Ph.D.<sup>3</sup>; (1)Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM; (2)College of Pharmacy and Health Sciences Department of Clinical Sciences, Drake University, Des Moines, IA; (3)Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Kansas City, KS*

### **Pharmacoepidemiology**

389. Assessment of Doctor Shopping for Zolpidem in Insomnia Outpatient in Taiwan.

*Tzu-Hsuan Lu, M.S.,<sup>1</sup> You-Meei Lin, M.S.,<sup>2</sup> Chiung-Hsuan Chiu, Ph.D.<sup>1</sup>; (1)School of Health Care Administration, Taipei Medical University, Taipei City, Taiwan; (2)Department of Pharmacy, Taipei Medical University – Shuang Ho Hospital, New Taipei City, Taiwan*

390. Knowledge and Attitude of Healthcare Professionals Toward Adverse Drug Reaction Reporting System in Saudi Arabia.

*Zuhair Alqahtani, Pharm.D.,<sup>1</sup> Mohammed Almoslem, Pharm.D.,<sup>1</sup> Shuroug Alowais, Pharm.D.,<sup>1</sup> Hisham Aljadhey, Pharm.D., Ph.D.,<sup>1</sup> Thamiir Alshammari, Ph.D., M.S., RPh<sup>2</sup>; (1)College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; (2)College of Pharmacy, Hail University, Hail, Saudi Arabia*

391. The Health Care Professional's Awareness and Attitude Toward Influenza Vaccines in Saudi Hospitals.

*Lama Alfehaid, Pharm.D.,<sup>1</sup> Joud Alfraih, Pharm.D.,<sup>1</sup> Zuhair Alqahtani, Pharm.D.,<sup>1</sup> Thamiir Alshammari, Ph.D., M.S., RPh<sup>2</sup>; (1)College of Pharmacy, King Saud University, Riyadh, Saudi Arabia; (2)College of Pharmacy, Hail University, Hail, Saudi Arabia*

### **Pharmacokinetics/Pharmacodynamics/Drug Metabolism/Drug Delivery**

392. Formulation of a Dry Powder Vaccine Containing *Listeria monocytogenes* for Immunization Against Tularemia.


*Alaa Elmaoued, M.S.,<sup>1</sup> Pavan Muttill, Ph.D.<sup>2</sup>; (1)College of Pharmacy, Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM; (2) Department of Pharmaceutical Sciences, University of New Mexico College of Pharmacy, Albuquerque, NM*



**Psychiatry**

393. Impact of Psychiatric Hospital Readmission Rates Through Pharmacist Intervention – A Retrospective Analysis.

*G.S. Shankar, M.S. (Public Health), M.S. (Psych), Pharm.D., BCPP; Department of Pharmacy Practice, College of Pharmacy, Western University of Health Sciences, Pomona, CA*



## The Great Eight—2013 Annual Meeting Best Paper Presentations

Monday, October 14

1:30 p.m.–3:30 p.m.

Convention Center:

Brazos

All Best Paper finalists will present their papers on Monday, October 14, 1:30 p.m.–3:30 p.m., during The Great Eight Platform Presentation. Finalists will also have posters displayed during the Scientific Poster Presentation sessions on October 14, October 15, and October 16. Presentation of the Best Paper Award will be on Tuesday, October 15, during the Scientific Poster Presentation, II session in the Fran Hill NE Exhibit Hall of the Albuquerque Convention Center.

*Moderator: P. David Rogers, Pharm.D., Ph.D., FCCP*

2013 ACCP Abstract Chair; First Tennessee Endowed Chair of Excellence in Clinical Pharmacy; Vice Chair for Research; Director, Clinical and Translational Therapeutics; Professor of Clinical Pharmacy and Pediatrics, University of Tennessee College of Pharmacy, Department of Clinical Pharmacy, Memphis, Tennessee

12F. Impact of a Medicaid Prescription Limitation Policy on Health Care Utilization.

*Megan Fleischman, Pharm.D.,<sup>1</sup> Deanne L. Hall, Pharm.D.,<sup>2</sup> Gary Fischer, M.D.,<sup>3</sup> John Donehoo, BS(Pharm),<sup>4</sup> Arletta Yahnke, BS(Pharm),<sup>4</sup> Ty Ridenour, Ph.D., MPE<sup>5</sup>; (1)Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA; (2)University of Pittsburgh School of Pharmacy/University of Pittsburgh Medical Center, Pittsburgh, PA; (3)University of Pittsburgh School of Medicine/University of Pittsburgh Medical Center; (4) University of Pittsburgh Medical Center; (5)University of Pittsburgh School of Pharmacy*

32F. Predictors of Medication Adherence: Results from the Atherosclerosis Risk in Communities Study.

*Jo E. Rodgers, Pharm.D., FCCP, BCPS (AQ Cardiology),<sup>1</sup> Carla A. Sueta, M.D., Ph.D.,<sup>2</sup> Anna Kucharska-Newton, Ph.D.,<sup>3</sup> Sally Stearns, Ph.D.,<sup>4</sup> Patricia Chang, M.D., MHS, FACC,<sup>5</sup> Hanyu Ni, Ph.D.,<sup>6</sup> Hadi Beyhaghi, M.D.,<sup>7</sup> Emily M. Thudium, Pharm.D., Lei Zhou, M.D.,<sup>7</sup> Elizabeth A. Blair, Pharm.D.,<sup>8</sup> Jerome Federspiel, Ph.D.<sup>7</sup>; (1)Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; (2)Division of Cardiology, School of Medicine, University of North Carolina, Chapel Hill, NC; (3)Epidemiology, UNC Gillings School of Public Health, Chapel Hill, NC; (4)Health Policy and Management, UNC Gillings School of Public Health, Chapel Hill, NC; (5)Department of Medicine, Division of Cardiology, University of North Carolina Health Care, Chapel Hill, NC; (6)Epidemiology, National Heart, Lung, and Blood Institute, Chapel Hill, NC; (7)UNC Gillings School of Public Health; (8)Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC*

158F. Adverse Drug Events Among Older Adults Discharged from Skilled Nursing Facilities to Home.

*Abir O. Kanaan, Pharm.D.,<sup>1</sup> Jennifer L. Donovan, Pharm.D.,<sup>1</sup> Terry S. Field, DSC,<sup>2</sup> Jessica Ogarek, M.S.,<sup>2</sup> Peggy Preusse, RN,<sup>2</sup> Devi Sundaresan, M.S.,<sup>2</sup> Shawn Gagne, B.A.,<sup>2</sup> Lawrence Garber, M.D.,<sup>2</sup> Jennifer Tjia, M.D., MSCE,<sup>2</sup> Sarah L. Cutrona, M.D., MPH,<sup>2</sup> Jerry H. Gurwitz, M.D.<sup>2</sup>; (1)MCPHS University, Worcester, MA; (2)Meyers Primary Care Institute, a joint endeavor of the University of Massachusetts Medical School, Reliant Medical Group, and Fallon Community Health Plan, Worcester, MA*

161F. Azithromycin-Associated Risk of Cardiovascular Death from Arrhythmia: A Review of the FDA Adverse Event Reporting System Database.

*Tina Khadem, Pharm.D.,<sup>1</sup> Robbert Van Manen, M.S.,<sup>2</sup> Jack Brown, Pharm.D., M.S.<sup>3</sup>*; (1)University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY; (2)Oracle Health Sciences Global Business Unit, Netherlands; (3)Strong Hospital, University of Rochester Medical Center, NY

196F. Assessment of Rabbit Antithymocyte Globulin Dosing and Clinical Outcomes in Kidney Transplantation.

*Heather Snyder, Pharm.D.,<sup>1</sup> Amy Krauss, Pharm.D., BCPS,<sup>2</sup> Vinaya Rao, M.D.,<sup>3</sup> Dagny Ulrich, Ph.D.,<sup>4</sup> Benjamin Duhart Jr, Pharm.D., M.S.<sup>1</sup>*; (1)Pharmacy, University of Tennessee Health Science Center/Methodist University Hospital, Memphis, TN; (2)Pharmacy Department, Methodist University Hospital, Memphis, TN; (3)Transplant Nephrology, University of Tennessee Health Science Center/Methodist University Hospital Transplant Institute, Memphis, TN; (4) Pharmacy, University of Tennessee Health Science Center, Memphis, TN

199F. Genetic Variations in a Sestrin2/Sestrin3/mTOR Axis and Development of New-Onset Diabetes After Transplantation in Hispanic Kidney Transplant Recipients.

*Don Vu, Pharm.D., Ph.D.,<sup>1</sup> Robert Naraghi, M.D.,<sup>2</sup> Ian V. Hutchinson, Ph.D., DSc,<sup>3</sup> Tariq Shah, M.D.,<sup>2</sup> David I. Min, Pharm.D.<sup>4</sup>*; (1)National Institute of Transplantation and Western University of Health Sciences, Los Angeles, CA; (2)National Institute of Transplantation and St. Vincent Medical Center, Los Angeles, CA; (3)USC School of Pharmacy, Los Angeles, CA; (4) Western University of Health Sciences, College of Pharmacy and National Institute of Transplantation, Los Angeles, CA

225F. Implementation and Evaluation of a New Sedation, Analgesia, and Delirium Order Set in a Large Community Hospital.

*Jonathan D. Edwards, Pharm.D.,<sup>1</sup> Adam Sawyer, Pharm.D.,<sup>2</sup> Katie Sims, Pharm.D.,<sup>2</sup> Edward Eiland III, Pharm.D., MBA<sup>3</sup>*; (1)Department of Pharmacy, Huntsville Hospital, Huntsville, AL; (2) Huntsville Hospital, Huntsville, AL; (3)Department of Pharmacy, Huntsville Hospital System, Huntsville, AL

234F. The "Clinical Pharmacy Priority (CP2) Score" to Prioritize Patients for Comprehensive Medication Review in Family Medicine.

*Joseph Vande Griend, Pharm.D.,<sup>1</sup> Joseph Saseen, Pharm.D.,<sup>1</sup> Debra Bislip, M.D.,<sup>2</sup> Colleen Conry, M.D.,<sup>2</sup> Caroline Emsermann, M.S.,<sup>2</sup> Wilson Pace, M.D.<sup>2</sup>*; (1)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; (2)University of Colorado School of Medicine

### **Best Paper Judging Committee:**

Joseph DiPiro  
Michael Gonyeau  
Mary Beth O'Connell  
Robert Parker  
Cynthia Sanoski

## Best Resident and Fellow Poster Finalists

All Best Resident and Fellow Poster finalists will have their posters displayed on Monday, October 14; Tuesday, October 15; and Wednesday, October 16. Finalists will present their posters on Monday, October 14, from 11:30 a.m. to 1:00 p.m. The presentation of the Best Resident and Fellow Poster Award will be on Monday, October 14, at 1:00 p.m. in the Fran Hill NE Exhibit Hall of the Albuquerque Convention Center.

84F. The Effects of Melatonin and Trazodone on Delirium in Hospitalized Patients.

*Lacey Shumate, Pharm.D.*,<sup>1</sup> Susan Fosnight, RPh, BCPS, CGP;<sup>2</sup> David DiNuoscio, M.D.,<sup>3</sup> Rex Wilford, D.O., RPh<sup>3</sup>; (1)Department of Pharmacy, Summa Health System, Akron, OH; (2) Northeast Ohio Medical University, Rootstown, OH; (3)Department of Internal Medicine, Summa Health System, Akron, OH

91F. Bleeding Outcomes in Patients Given Clopidogrel Within 5 Days of Robotic Coronary Artery Bypass Graft Procedure.

*Sophia Vainrub, Pharm.D.*,<sup>1</sup> Asad Patanwala, Pharm.D.,<sup>1</sup> Richard Cosgrove, Pharm.D.,<sup>2</sup> Robert Poston, M.D.,<sup>3</sup> Paul Nolan, Pharm.D.<sup>1</sup>; (1)Pharmacy Practice and Science, The University of Arizona; (2)Pharmacy Services, University of Arizona Medical Center; (3)Surgery, The University of Arizona

92F. Efficacy of Once-Daily Enoxaparin for the Prevention of Venous Thromboembolism in Hospitalized Obese Patients.

*Carmen B. Smith, Pharm.D.*,<sup>1</sup> Lena Maynor, Pharm.D.,<sup>2</sup> Jay L. Martello, Pharm.D., BCPS<sup>2</sup>; (1) West Virginia University Healthcare, Morgantown, WV; (2)West Virginia University School of Pharmacy, Morgantown, WV

123F. Incidence of Vancomycin-Induced Nephrotoxicity in Hospitalized Patients With and Without Concomitant Piperacillin-Tazobactam.

*Lindsey Burgess, Pharm.D.*, Richard Drew, Pharm.D., M.S., FCCP, BCPS; Duke University Hospital, Durham, NC

190F. Evaluation of Alemtuzumab vs. Basiliximab Induction in Lung Transplantation.

*Laura Whited, Pharm.D.*,<sup>1</sup> Mike Latran, Pharm.D.,<sup>1</sup> Chadi Hage, M.D.,<sup>2</sup> Michael Duncan, M.D.,<sup>2</sup> I-wen Wang, M.D., Ph.D.,<sup>2</sup> David Roe, M.D.,<sup>2</sup> Thomas Wozniak, M.D.<sup>2</sup>; (1)Pharmacy, IU Health Methodist Hospital, Indianapolis, IN; (2)IU Health Methodist Hospital

### Best Resident and Fellow Poster Judging Committee:

Sheryl Chow, Chair  
Rachel Couchenour  
Douglas Jennings  
Jean Nappi  
Michael Peeters

## Best Student Poster Finalists

All Best Student Poster finalists will have their posters displayed on Monday, October 14, Tuesday, October 15, and Wednesday, October 16. Finalists will present their posters on Monday, October 22, from 11:30 a.m. to 1:00 p.m. The presentation of the Best Student Poster Award will be on Monday, October 14, at 1:00 p.m. in the Fran Hill NE Exhibit Hall of the Albuquerque Convention Center.

304F. Assessment of Adverse Events and Predictors of Neurologic Recovery of an Institution-Specific Therapeutic Hypothermia Protocol.

*Jolie Gallagher, Pharm.D. Candidate*,<sup>1</sup> Robert MacLaren, Pharm.D.,<sup>2</sup> Sara Varnado, Pharm.D., Lam Nguyen, Pharm.D., John Shin, Pharm.D.<sup>1</sup>; (1)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; (2)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO

316F. Pharmacodynamic Effects of Low-Dose Pioglitazone in Nondiabetic Patients with the Metabolic Syndrome.

*Anh Vu, Pharm.D. Candidate*,<sup>1</sup> Amber Beitelshees, Pharm.D., MPH,<sup>2</sup> Ronald Prigeon, M.D.,<sup>2</sup> Maha Sidhom, B.A.,<sup>1</sup> Brooke Bredbeck, B.S.,<sup>1</sup> Julie Predhomme, ANP,<sup>1</sup> Lisa Kosmiski, M.D.,<sup>3</sup> Christina Aquilante, Pharm.D.<sup>1</sup>; (1)University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO; (2)University of Maryland, Baltimore; (3)University of Colorado School of Medicine, Aurora, CO

321F. Novel Double and Triple Antibiotic Combinations at Clinically Relevant Concentrations Against Polymyxin B-Resistant *Pseudomonas aeruginosa*.

*Michael D. Bear, Pharm.D. Candidate*, Amy Suen, Pharm.D. Candidate, Justin Lenhard, Pharm.D. Candidate, Zackery Bulman, Pharm.D. Candidate, Neang S. Ly, Ph.D. Candidate, Gauri Rao, Pharm.D., Patricia N. Holden, B.S., Brian T. Tsuji, Pharm.D.; University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY

322F. A Retrospective Evaluation of the Effectiveness of Vancomycin Continuous Infusion versus Intermittent Dosing.

*Kimberly J. Won, Pharm.D. Candidate*, Tyree H. Kiser, Pharm.D., FCCP, BCPS; University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO

343F. Bile Acid-Induced Apoptosis and Inflammation Are Attenuated by Omega-3 Long-Chain Polyunsaturated Fatty Acids in a Macrophage Model.

*Timothy Howze, B.S.*, Peihong Guan, B.S., Richard A. Helms, Pharm.D., Emma M. Tillman, Pharm.D.; University of Tennessee Health Science Center, Memphis, TN

379F. *Clostridium difficile* Following Solid Organ Transplantation.

*Jennifer Miao, Pharm.D. Candidate*, Jaclyn Powell, Pharm.D., Spencer Martin, Pharm.D., BCPS, Shreya Shah, Pharm.D., Keith Fester, Pharm.D., Jenna Scheffert, Pharm.D., Demetra Tsapepas, Pharm.D., BCPS; NY-Presbyterian Hospital-Columbia University Medical Center, New York, NY

### Best Student Poster Judging Committee:

Mary Lee, Chair  
Roland Dickerson  
Lee Evans  
David Min  
Julie Murphy